Sanara MedTech (SMTI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Board of directors and corporate governance
Sara N. Ortwein will be appointed as Lead Independent Director for a three-year term, contingent on her election at the Annual Meeting, with additional annual compensation of $40,000.
The Lead Independent Director's duties include preparing and reviewing Board meeting agendas and minutes, handling board issues, and presiding over executive sessions.
Rozell Mack III will become chair of the Compensation Committee, contingent on his election, while Ms. Ortwein will remain a committee member.
Ronald T. Nixon's title will change from Executive Chairman to Chairman, effective as of the Annual Meeting and contingent on his election.
Voting matters and shareholder proposals
The supplement amends the previously filed Proxy Statement for the 2026 Annual Meeting scheduled for June 4, 2026.
All previously distributed proxy cards remain valid; no new proxy card or voting instructions are required unless shareholders wish to change their vote.
Shareholders may revoke or change their proxy vote as described in the Proxy Statement.
Executive compensation and say-on-pay
The Lead Independent Director will receive an additional annual cash payment of $40,000, paid quarterly, for her service.
Latest events from Sanara MedTech
- Annual Meeting to vote on directors, auditor, and executive pay, with board recommendations.SMTI
Proxy filing17 Apr 2026 - Virtual annual meeting to vote on directors, auditor, executive pay, and governance matters.SMTI
Proxy filing17 Apr 2026 - Record 2025 revenue and margin, with 2026 growth outlook driven by surgical and market expansion.SMTI
Q4 202524 Mar 2026 - Pure-play surgical wound care focus, strong growth, and new product launches drive future outlook.SMTI
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - All agenda items, including director elections and governance changes, were approved.SMTI
AGM 20242 Feb 2026 - Q2 2024 revenue up 28% to $20.2M; gross margin 90%; net loss $3.5M; THP launch in 2025.SMTI
Q2 20241 Feb 2026 - Record Q3 revenue and EBITDA growth, but higher costs led to a larger net loss.SMTI
Q3 202414 Jan 2026 - Record Q3 revenue and strong growth reflect expanding adoption of advanced wound care platforms.SMTI
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Strong Q2 growth, leadership transition, and a promising product pipeline set the stage for expansion.SMTI
Cantor Global Healthcare Conference 202531 Dec 2025